These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31596520)

  • 1. Anemia management in cancer patients with chronic kidney disease.
    Latcha S
    Semin Dial; 2019 Nov; 32(6):513-519. PubMed ID: 31596520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
    Thavarajah S; Choi MJ
    Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
    Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
    Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary.
    Musio F
    Expert Rev Hematol; 2020 Nov; 13(11):1175-1188. PubMed ID: 33028115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin: the swinging pendulum.
    Oster HS; Neumann D; Hoffman M; Mittelman M
    Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
    Hazzan AD; Shah HH; Hong S; Sakhiya V; Wanchoo R; Fishbane S
    Kidney Int; 2014 Jul; 86(1):34-9. PubMed ID: 24402094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
    BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
    Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
    Moist LM; Troyanov S; White CT; Wazny LD; Wilson JA; McFarlane P; Harwood L; Sood MM; Soroka SD; Bass A; Manns BJ
    Am J Kidney Dis; 2013 Nov; 62(5):860-73. PubMed ID: 24054466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Lupus Erythematosus as a Rare Cause of Anemia Resistant to Erythropoiesis-stimulating Agents.
    Yenigun EC; Bayrakci N; Cevher SK; Ozkayar N; Dede F
    Iran J Kidney Dis; 2016 Mar; 10(2):97-9. PubMed ID: 26921753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease.
    Rashidi A; Garimella PS; Al-Asaad A; Kharadjian T; Torres MN; Thakkar J
    Adv Chronic Kidney Dis; 2022 Mar; 29(2):180-187.e1. PubMed ID: 35817525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).
    Park H; Liu X; Henry L; Harman J; Ross EA
    BMC Nephrol; 2018 Nov; 19(1):318. PubMed ID: 30413150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
    Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
    Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of anemia in chronic kidney disease--position statement of the Croatian Society for Nephrology, Dialysis and Transplantation and review of the KDIGO and ERPB guidelines].
    Rački S; Bašić-Jukić N; Kes P; Ljutić D; Lovčić V; Prkačin I; Radić J; Vujičić B; Bubić I; Jakić M; Belavić Ž; Sefer S; Pehai M; Klarić D; Gulin M;
    Acta Med Croatica; 2014 Apr; 68(2):215-21. PubMed ID: 26012163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.